California Public Employees Retirement System raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 0.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 192,211 shares of the biotechnology company’s stock after buying an additional 947 shares during the quarter. California Public Employees Retirement System owned approximately 0.22% of Sarepta Therapeutics worth $24,907,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in SRPT. Two Sigma Investments LP lifted its holdings in Sarepta Therapeutics by 2,475.1% in the 3rd quarter. Two Sigma Investments LP now owns 789,712 shares of the biotechnology company’s stock valued at $87,295,000 after acquiring an additional 759,045 shares during the last quarter. Wellington Management Group LLP boosted its position in Sarepta Therapeutics by 33.6% during the first quarter. Wellington Management Group LLP now owns 2,680,478 shares of the biotechnology company’s stock worth $209,399,000 after purchasing an additional 673,725 shares during the period. Thrivent Financial for Lutherans boosted its position in Sarepta Therapeutics by 509.2% during the third quarter. Thrivent Financial for Lutherans now owns 699,483 shares of the biotechnology company’s stock worth $77,321,000 after purchasing an additional 584,654 shares during the period. Pictet Asset Management SA boosted its position in Sarepta Therapeutics by 459.7% during the third quarter. Pictet Asset Management SA now owns 667,044 shares of the biotechnology company’s stock worth $73,735,000 after purchasing an additional 547,857 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Sarepta Therapeutics by 124.8% in the third quarter. Renaissance Technologies LLC now owns 884,178 shares of the biotechnology company’s stock valued at $97,737,000 after acquiring an additional 490,900 shares during the period. 87.31% of the stock is currently owned by institutional investors.
Sarepta Therapeutics Stock Performance
Shares of Sarepta Therapeutics stock opened at $121.27 on Thursday. The business’s fifty day simple moving average is $134.30 and its 200 day simple moving average is $125.21. The firm has a market capitalization of $11.30 billion, a P/E ratio of -9.56 and a beta of 1.02. Sarepta Therapeutics, Inc. has a 12 month low of $61.28 and a 12 month high of $159.84. The company has a current ratio of 4.63, a quick ratio of 4.26 and a debt-to-equity ratio of 1.73.
Wall Street Analyst Weigh In
A number of research analysts recently commented on SRPT shares. Oppenheimer cut their target price on Sarepta Therapeutics from $180.00 to $150.00 and set an “outperform” rating for the company in a research note on Thursday, March 9th. Citigroup initiated coverage on Sarepta Therapeutics in a report on Tuesday, April 4th. They set a “buy” rating and a $179.00 price objective on the stock. Needham & Company LLC lowered their price target on Sarepta Therapeutics from $200.00 to $160.00 and set a “buy” rating on the stock in a research report on Friday, March 17th. StockNews.com initiated coverage on Sarepta Therapeutics in a research report on Thursday, March 16th. They set a “hold” rating for the company. Finally, The Goldman Sachs Group upped their target price on Sarepta Therapeutics from $171.00 to $190.00 and gave the company a “buy” rating in a research report on Wednesday, March 1st. Two analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $167.47.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Featured Stories
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- Occidental Petroleum: Will Buffet Buy More?
- 5 Best Healthcare Sector ETFs
- Electronic Arts Has Game But Can Share Price Move Higher?
- Wendy’s May Have Just Become A Value Play
- Rivian Leads EV Startups But Will The Stock Move Higher?
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
